首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Effect of CCK receptor antagonists on the antinociceptive reinforcing and gut motility properties of morphine.
【2h】

Effect of CCK receptor antagonists on the antinociceptive reinforcing and gut motility properties of morphine.

机译:CCK受体拮抗剂对吗啡的抗伤害增强和肠道运动特性的影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The ability of a selective CCKA receptor antagonist PD 140548 and a selective CCKB receptor antagonist CI-988 (formerly PD 134308) to modulate the various in vivo properties of morphine was investigated in the rat. 2. PD 140548 dose-dependently (0.001-1.0 mg kg-1, i.p.) antagonised the development of conditioned place preference to morphine (2.0 mg kg-1, s.c.). In contrast, CI-988 (0.01-1.0 mg kg-1, i.p.) did not affect this morphine-induced behaviour. Neither of the CCK receptor antagonists blocked or generalised to the morphine (3.0 mg kg-1, i.p.) discriminative stimulus. 3. CI-988 (0.001-10.0 mg kg-1, s.c.) at doses of 0.05 and 0.1 mg kg-1 (s.c.), potentiated the antinociceptive action of a threshold dose of morphine (5.0 mg kg-1, i.p.) in a radiant heat model of acute nociception, the rat tail flick test. Furthermore, at 0.01 mg kg-1 it potentiated the antinociceptive action of morphine (3.0 mg kg-1) during the acute phase of the rat paw formalin test. And at doses of 0.01 and 0.1 mg kg-1 it also potentiated the antinociceptive action of morphine (1.0 mg kg-1) during the tonic phase of the formalin test. However, in both models, higher doses of CI-988 were ineffective. In contrast, PD 140548 (0.001-10 mg kg-1, s.c.) was only active at a dose of 1.0 mg kg-1 (s.c.) and only in the tonic phase of the formalin test. Neither CI-988 nor PD 140548 possessed any intrinsic antinociceptive action in either of the tests. Chronic treatment with CI-988 (0.01 mg kg-1, s.c.) prevented the development of tolerance to morphine antinociception (4 mg kg-1, s.c.) following a 6 day period of twice daily injections of morphine escalating from 1 to 16 mg kg-1 (i.p.). 4. Morphine dose-dependently (1-10 mg kg-1, s.c.) reduced the distance travelled by a charcoal meal in the rat intestine. Neither PD 140548 (0.01-1.0 mg kg-1, i.p.) nor CI-988 (0.01-1.0 mg kg-1, i.p.) potentiated or suppressed this inhibitory action of morphine. 5. In conclusion, the results of the present study indicate that CCKA and CCKB receptors modulate different properties of morphine. Thus, whilst a selective CCKA receptor antagonist blocked the rewarding properties of morphine, a selective CCKB receptor antagonist potentiated the antinociceptive action. However, neither compound displayed a potential for modulating the influence of morphine on gastro-intestinal motility. It is suggested that these findings may have important implications for development of CCK receptor antagonists as analgesic adjuncts to the therapeutic use of morphine.
机译:1.在大鼠中研究了选择性CCKA受体拮抗剂PD 140548和选择性CCKB受体拮抗剂CI-988(以前称为PD 134308)调节吗啡各种体内特性的能力。 2. PD 140548剂量依赖性地(0.001-1.0 mg kg-1,腹膜内)拮抗了对吗啡(2.0 mg kg-1,s.c。)的条件性场所偏爱的发展。相反,CI-988(0.01-1.0 mg kg-1,i.p.)不会影响这种吗啡诱导的行为。两种CCK受体拮抗剂均未阻止或泛化吗啡(3.0 mg kg-1,i.p.)歧视性刺激。 3.以0.05和0.1 mg kg-1(sc)的剂量服用CI-988(0.001-10.0 mg kg-1,sc),可增强吗啡阈剂量(5.0 mg kg-1,ip)的抗伤害感受作用。急性伤害感受辐射热模型,大鼠甩尾试验。此外,在大鼠爪福尔马林试验的急性期,其剂量为0.01 mg kg-1时,可增强吗啡的镇痛作用(3.0 mg kg-1)。在0.01和0.1 mg kg-1的剂量下,它在福尔马林试验的强直阶段也增强了吗啡的镇痛作用(1.0 mg kg-1)。但是,在两个模型中,较高剂量的CI-988均无效。相比之下,PD 140548(0.001-10 mg kg-1,s.c.)仅在1.0 mg kg-1(s.c.)的剂量下才有效,并且仅在福尔马林试验的强直阶段有效。在任何一项测试中,CI-988和PD 140548都不具有任何固有的抗伤害感受作用。在每天注射两次吗啡的6天期间(从1毫克逐渐升至16毫克千克),用CI-988(0.01 mg kg-1,sc)进行长期治疗可防止对吗啡抗伤害感受的耐受性(4 mg kg-1,sc)的发展。 -1(ip)。 4.吗啡剂量依赖性地(1-10 mg kg-1,s.c。)减少了木炭粉在大鼠肠中的传播距离。 PD 140548(0.01-1.0 mg kg-1,i.p.)和CI-988(0.01-1.0 mg kg-1,i.p.)均未增强或抑制吗啡的这种抑制作用。 5.总之,本研究的结果表明CCKA和CCKB受体调节吗啡的不同特性。因此,尽管选择性的CCKA受体拮抗剂阻断了吗啡的奖励特性,但选择性的CCKB受体拮抗剂却增强了抗伤害感受的作用。但是,这两种化合物均未显示出调节吗啡对胃肠动力的影响的潜力。提示这些发现可能对CCK受体拮抗剂作为吗啡治疗用途的止痛剂的开发具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号